Stockreport

NEXGEL expects pro forma annual revenue of roughly $35M following Celularity wound segment acquisition [Seeking Alpha]

Celularity Inc. - Class A  (CELU) 
PDF "On today's call, I will discuss our announcement this morning regarding the closing of our transaction to acquire Celularity's degenerative wound segment." (CEO, Presi [Read more]